psoriasis, biologics, tnf-alfa remmers, etanercept, adalimumab, ustekinumab, dosis reductie, dose reduction, dose decrease
Conditions
Interventions
Lowering frequency of biologic given
Sponsors
Radboudumc, Nijmegen, The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: (1) Treatment of at least 6 months with one biologic (2) During the last 6 months, subsequent low disease activity scores (PASI (psoriasis area and severity index) <5) until the moment of inclusion. At least 2 PASI scores should be available. (3) Good disease-related quality of life (DLQI (dermatology life quality index) ≤5) at the moment of inclusion in the study • Established diagnosis of plaque psoriasis. • Receiving treatment with adalimumab, etanercept, or ustekinumab. • Age ≥18 years.
Exclusion criteria
Exclusion criteria: • Psoriasis itself is not the main reason for biologic prescription (e.g. when a patient has RA and psoriasis, and RA is the main reason for the biologic). • Concomitant use of immunosupressants other than methotrexate or acitretin for psoriasis. • Severe comorbidities with short life-expectancy (e.g. metastasized tumour). • Presumed inability to follow the study protocol. • Infliximab use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity Index (PASI) at 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology Life Quality Index (DLQI) at 12 months PASI scores at each time point Time until flare Trough level antidrug antibodies and serum drug levels at each time point hsCRP at each time point SAEs | — |
Contacts
Public ContactJMPA van den Reek
Outcome results
None listed